NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
20 Dec 2012

TiGenix Completes Private Placement Raising EUR 6.7 million

Leuven, Belgium – 20 December 2012 – TiGenix NV (Euronext Brussels: TIG) announces today that it has raised EUR 6.7 million through a private placement via the accelerated bookbuilding procedure announced on 19 December 2012 after the market closed.
19 Dec 2012

TiGenix reports positive interim safety results of its Phase IIa study of Cx611

Leuven (BELGIUM), Madrid (SPAIN) – December 19, 2012 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, announced today positive interim safety results of its Phase IIa study of Cx611 in rheumatoid arthritis (RA).
19 Dec 2012

TiGenix to Raise Capital via a Private Placement of New Ordinary Shares

Leuven, Belgium – 19 December 2012 – TiGenix NV (Euronext Brussels: TIG) today announced that it will launch a private placement of up to 8,629,385 new ordinary shares.
06 Dec 2012

Endosense appoints Nicolas Marsault as new CFO

GENEVA – December 6, 2012 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has named Nicolas Marsault as its new chief financial officer.
27 Nov 2012

Endosense secures USD 40.3M/CHF 37.4M Series C financing

GENEVA – November 27, 2012 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced the close of a USD 40.3 million/CHF 37.4 million series C financing.
23 Nov 2012

TiGenix focus on advanced cell therapy programs

Leuven (BELGIUM) – November 23, 2012 – TiGenix (Euronext Brussels: TIG), the European leader in cell therapy, announced today the definitive closure of its biomaterials unit, TiGenix Ltd., to allow the company to fully focus on the further commercial roll-out of ChondroCelect®, and its cell therapy product development pipeline.
Inbiomotion creates a world class Scientific Advisory Board chaired by Prof. Rob E. Coleman<
21 Nov 2012

Inbiomotion creates a world class Scientific Advisory Board chaired by Prof. Rob E. Coleman

Scientific Advisory Board with renowned experts in various disciplines, including bone metastatic disease, biomarker development, translational research and medical oncology.
13 Nov 2012

TiGenix signs agreement for commercialization of ChondroCelect in the Middle East

Leuven (Belgium) – November 13, 2012 – TiGenix NV (Euronext Brussels: TIG) and pharmaceutical marketing and distribution company Genpharm in Dubai, United Arab Emirates, today announced that they have signed an exclusive agreement for the commercialization of ChondroCelect® in the Middle East region.
Jon Askaa joins Inbiomotion Board of Directors – Management team strengthened<
08 Nov 2012

Jon Askaa joins Inbiomotion Board of Directors – Management team strengthened

Inbiomotion is a company focused on the development of biomarkers for the prediction of bone metastasis
08 Nov 2012

TiGenix Business Update & Financial Highlights for Q3 of 2012

Leuven (BELGIUM) – November 8, 2012 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the third quarter ending September 30, 2012.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.